Patents by Inventor Taro ASABA

Taro ASABA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY
    Publication number: 20260183424
    Abstract: The present disclosure provides an ionizable lipid that can be used for nucleic acid delivery into cytoplasm. An ionizable lipid of the present disclosure is, for example, a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 24, 2025
    Publication date: July 2, 2026
    Inventors: Kenzo ARAI, Masashi SEKI, Yosuke KABURAGI, Taro ASABA, Seiji HITAOKA, Takayuki MIYAZAKI, Yasuaki KAMADA, Michael Geoffrey Neil RUSSELL, James Lusher STRACHAN, Stephen Carl MCKEOWN
  • CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF
    Publication number: 20250051322
    Abstract: Crystals of compounds represented by formula (I) having potential as drug substances for pharmaceuticals, as well as salts of compounds represented by formula (I) and their crystals.
    Type: Application
    Filed: January 12, 2023
    Publication date: February 13, 2025
    Inventors: Ikuo Kushida, Yoko Ito, So Yasui, Takashi Fukuyama, Nobuaki Sato, Taro Asaba
  • Substituted piperidine compounds and their use
    Patent number: 11479552
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 25, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yu Yoshida, Yoichi Kita, Makoto Kotake, Keiichi Sorimachi, Toshiyuki Ohfusa, Takafumi Motoki, Taro Asaba
  • SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE
    Publication number: 20220017517
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 20, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yu YOSHIDA, Yoichi KITA, Makoto KOTAKE, Keiichi SORIMACHI, Toshiyuki OHFUSA, Takafumi MOTOKI, Taro ASABA